Citations

Clear

185 citation(s) found for "Petrucelli, Leonard".

P1‐371: Characteristics of cytosolic hyperphosphorylated tau species in rTg4510 mouse brain
DeTure, Michael , Ebrahim, Abdul-Shukkur, Christensen, S⊘ren, Kang, Dongcheul, Knight, Josh , Petrucelli, Leonard , Yen, Shu‐Hui, Lewis, Jada , Sahara, Naruhiko , Volbracht, Christiane

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2010.05.925 Get It

P1‐185: Wild‐type human TDP‐43 induces mitochondrial abnormalities and axonal degeneration in transgenic mice
Xu, Yafei , Lin, Wen-Lang, D’Alton, Simon , Sheng, Hong, Casey, Monica Castanedes, Tong, Jimei, Yu, Xin , Rademakers, Rosa , Hutton, Mike, Petrucelli, Leonard , Lewis, Jada , Gendron, Tania F. , Zhang, Yong‐Jie , Sheng, Hong, Crook, Richard , Knight, Joshua A. , Boylan, Khrista , McGowan, Eileen , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2010.05.735 Get It

P1‐179: Inducible expression of wild‐type TDP‐43 is toxic to mouse hippocampal and cortical neurons
Xu, Yafei , Petrucelli, Leonard , Lewis, Jada , Cannon, Ashley , Zhang, Yong‐Jie , Knight, Joshua A. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2010.05.729 Get It

P1‐165: Generation and characterization of FTLD‐U and ALS cell model with inducible expression of TDP‐43 C‐terminal fragment
Xu, Yafei , Ko, Li‐wen, Yen, Shu‐Hui, Petrucelli, Leonard , Zhang, Yongjie , Gendron, Tania F.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2010.05.715 Get It

S5‐01‐01: Modeling TDP43 proteinopathies
Petrucelli, Leonard

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2010.05.516 Get It

Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity
Zhang, Yong‐Jie , Xu, Ya-Fei, Cook, Casey , Roettges, Paul S., Link, Christopher D. , Lin, Wen-Lang, Tong, Jimei, Castanedes‐Casey, Monica , Ash, Peter E.A. , Gass, Jennifer , Rangachari, Vijayaraghavan , Buratti, Emanuele , Golde, Todd E. , Dickson, Dennis W. , Petrucelli, Leonard , Gendron, Tania F. , Baralle, Francisco Ernesto , Zhang, Yong-Jie , Dickson, Dennis W

Mayo Clinic

Proceedings of the National Academy of Sciences | April 21, 2009 | Volume: 106 | Issue: 18 | Pages: 7607-7612

10.1073/pnas.0900688106 | PMID 19383787 Get It

Inclusions of TAR DNA-binding protein-43 (TDP-43), a nuclear protein that regulates transcription and RNA splicing, are the defining histopathological feature of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-Us) and sporadic and familial forms of amyotrophic lateral sclerosis (ALS). In ALS and FTLD-U, aggregated, ubiquitinated, and N-terminally truncated TDP-43 can be isolated from brain tissue rich in neuronal and glial cytoplasmic inclusions. The loss of TDP-43 function resulting from inappropriate cleavage, translocation from the nucleus, or its sequestration into inclusions could play important roles in neurodegeneration. However, it is not known whether TDP-43 fragments directly mediate toxicity and, more specifically, whether their abnormal aggregation is a cause or consequence of pathogenesis. We report that the ectopic expression of a ≈25-kDa TDP-43 fragment corresponding to the C-terminal truncation product of caspase-cleaved TDP-43 leads to the formation of toxic, insoluble, and ubiquitin- and phospho-positive cytoplasmic inclusions within cells. The 25-kDa C-terminal fragment is more prone to phosphorylation at S409/S410 than full-length TDP-43, but phosphorylation at these sites is not required for inclusion formation or toxicity. Although this fragment shows no biological activity, its exogenous expression neither inhibits the function nor causes the sequestration of full-length nuclear TDP-43, suggesting that the 25-kDa fragment can induce cell death through a toxic gain-of-function. Finally, by generating a conformation-dependent antibody that detects C-terminal fragments, we show that this toxic cleavage product is specific for pathologic inclusions in human TDP-43 proteinopathies.
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity
Ko, Han Seok , Bailey, Rachel M. , Smith, Wanli W. , Liu, Zhaohui , Shin, Joo‐Ho , Lee, Yun-Il, Zhang, Yong‐Jie , Jiang, Haibing , Ross, Christopher A. , Moore, Darren J. , Patterson, Cam, Petrucelli, Leonard , Dawson, Ted M. , Dawson, Valina L. , Zhang, Yong-Jie , Ross, Christopher A , Dawson, Valina L

Mayo Clinic

Proceedings of the National Academy of Sciences | February 7, 2009 | Volume: 106 | Issue: 8 | Pages: 2897-2902

10.1073/pnas.0810123106 | PMID 19196961 Get It

Mutation in leucine-rich repeat kinase-2 ( LRRK2 ) is the most common cause of late-onset Parkinson's disease (PD). Although most cases of PD are sporadic, some are inherited, including those caused by LRRK2 mutations. Because these mutations may be associated with a toxic gain of function, controlling the expression of LRRK2 may decrease its cytotoxicity. Here we show that the carboxyl terminus of HSP70-interacting protein (CHIP) binds, ubiquitinates, and promotes the ubiquitin proteasomal degradation of LRRK2. Overexpression of CHIP protects against and knockdown of CHIP exacerbates toxicity mediated by mutant LRRK2. Moreover, HSP90 forms a complex with LRRK2, and inhibition of HSP90 chaperone activity by 17AAG leads to proteasomal degradation of LRRK2, resulting in increased cell viability. Thus, increasing CHIP E3 ligase activity and blocking HSP90 chaperone activity can prevent the deleterious effects of LRRK2. These findings point to potential treatment options for LRRK2-associated PD.
Structural determinants of the cellular localization and shuttling of TDP-43
Ayala, Youhna M., Zago, Paola, D’Ambrogio, Andrea , Xu, Ya-Fei, Petrucelli, Leonard , Buratti, Emanuele , Baralle, Francisco Ernesto

Mayo Clinic

Journal of Cell Science | October 28, 2008 | Volume: 121 | Issue: 22 | Pages: 3778-3785

10.1242/jcs.038950 | PMID 18957508 Get It

TDP-43 (also known as TARDBP) regulates different processes of gene expression, including transcription and splicing, through RNA and DNA binding. Moreover, recent reports have shown that the protein interacts with the 3′UTRs of specific mRNAs. The aberrant cellular distribution and aggregation of TDP-43 were recently reported in neurodegenerative diseases, namely frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A detailed description of the determinants for cellular localization has yet to emerge, including information on how the known functions of TDP-43 and cellular targeting affect each other. We provide the first experimental evidence that TDP-43 continuously shuttles between nucleus and cytoplasm in a transcription-dependent manner. Furthermore, we investigate the role of the functional TDP-43 domains in determining cellular targeting through a combination of immunofluorescence and biochemical fractionation methods. Our analyses indicate that the C-terminus is essential for solubility and cellular localization, because its deletion results in the formation of large nuclear and cytoplasmic aggregates. Disruption of the RNA-recognition domain required for RNA and DNA binding, however, alters nuclear distribution by decreasing TDP-43 presence in the nucleoplasm. Our findings suggest that TDP-43 solubility and localization are particularly sensitive to disruptions that extend beyond the newly found nuclear localization signal and depend on a combination of factors that are closely connected to the functional properties of this protein.
S2‐03–03: Tau degradation and therapy
Petrucelli, Leonard

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2008.05.285 Get It

O1‐06–03: Akt functions to regulate the chaperone complex and attenuate Tau degradation
Dickey, Chad A. , Xu, Yafei , Jinwal, Umesh K., Bailey, Rachel M. , Dunmore, Judith, Morgan, Dave, Petrucelli, Leonard , Koren, John , Zhang, Yong‐Jie , Birnbaum, Morris J.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2008.05.258 Get It